Zynex (Nasdaq:ZYXI) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ZYXI 주식 개요

는 자회사와 함께 만성 및 급성 통증을 치료하고, 전기 자극을 통해 재활 목적으로 근육을 활성화하고 운동하는 의료 기기를 설계, 제조 및 판매합니다.

ZYXI 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	4/6
과거 실적	2/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 86.6% 에서 거래

수익은 매년 37.29% 증가할 것으로 예상됩니다.

위험 분석

부채비율이 높네요

이익 마진 (4.3%) 작년보다 낮습니다 (10.2%)

Zynex, Inc. 경쟁사

Tactile Systems Technology

NasdaqGM:TCMD

US$273.0m

Semler Scientific

NasdaqCM:SMLR

US$263.2m

IRADIMED

NasdaqGM:IRMD

US$535.8m

Jin Medical International

NasdaqCM:ZJYL

US$486.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Zynex
과거 주가
현재 주가	US$9.18
52주 최고치	US$13.77
52주 최저치	US$6.88
베타	0.62
11개월 변경	-13.23%
3개월 변경 사항	-28.11%
1년 변경 사항	-2.96%
33년 변화	-37.12%
5년 변화	16.20%
IPO 이후 변화	329.70%

최근 뉴스 및 업데이트

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

주주 수익률

	ZYXI	US Medical Equipment	US 마켓
7D	0.5%	0.4%	0.4%
1Y	-3.0%	-0.6%	22.9%

수익률 대 산업: ZYXI 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ZYXI 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ZYXI's price volatile compared to industry and market?
ZYXI volatility
ZYXI Average Weekly Movement	5.2%
Medical Equipment Industry Average Movement	7.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ZYXI 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ZYXI 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1996	1,100	Thomas Sandgaard	www.zynex.com

는 자회사와 함께 만성 및 급성 통증을 치료하고, 전기 자극을 통해 재활 목적으로 근육을 활성화하고 운동하는 의료 기기를 설계, 제조 및 판매합니다. 회사는 현장 영업 담당자를 통해 의사와 치료사에게 판매되는 이중 채널, 다중 모드 간섭 전류, 경피 전기 신경 자극 및 신경근 전기 자극(NMES) 기기인 넥스웨이브, 근전도 및 전기 자극 기술 기기인 뉴로무브, 여성 요실금 치료를 위한 전기 자극 제품인 인웨이브, NMES 기기인 E-Wave, NMES 기기인 M-Wave를 제공합니다. 또한 신체에 전류를 전달하는 전극과 전기 치료 제품에 사용되는 배터리를 포함한 자체 브랜드 제품도 공급합니다.

Zynex, Inc. 기본 사항 요약

Zynex 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ZYXI 기본 통계
시가총액	US$290.43m
수익(TTM)	US$8.17m
수익(TTM)	US$188.68m

35.7x

P/E 비율

1.5x

P/S 비율

ZYXI 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ZYXI 손익 계산서(TTM)
수익	US$188.68m
수익 비용	US$38.06m
총 이익	US$150.63m
기타 비용	US$142.46m
수익	US$8.17m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.26
총 마진	79.83%
순이익 마진	4.33%
부채/자본 비율	174.7%

ZYXI 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ZYXI 주식 개요

보상

위험 분석

Zynex, Inc. 경쟁사

NasdaqGM:TCMD

US$273.0m

NasdaqCM:SMLR

US$263.2m

NasdaqGM:IRMD

US$535.8m

NasdaqCM:ZJYL

US$486.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain